In this issue:
Combined immune checkpoint inhibition in advanced colorectal cancer
Prognostic value of tumor deposits in stage III colon cancer
Pembrolizumab for PD-L1 positive advanced carcinoid or pancreatic neuroendocrine tumours
Ivosidenib in IDH1-mutant cholangiocarcinoma
Pemigatinib for first-line metastatic cholangiocarcinoma
Nivolumab for advanced refractory BTC
Trastuzumab in HER2-positive advanced G/GOC cancer
Preoperative chemoradiotherapy vs immediate surgery for pancreatic cancer
Cabozantinib for metastatic gastrointestinal stromal tumour after previous TKI treatment
BRAF-mutant transcriptional subtype biomarkers in colorectal cancer
Please login below to download this issue (PDF)